Education
About Us
Working with TipRanks
Follow Us
CSL (AU:CSL)
ASX:CSL
Earnings Data
Report Date
Feb 18, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
6.94Last Year’s EPS
6.61Same Quarter Last Year
Moderate Buy
Based on 14 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
CSL demonstrated strong financial growth and strategic initiatives, including successful product launches and plans to streamline operations and enhance R&D efficiency. However, challenges remain in the form of U.S. policy impacts, competitive pressures in the iron market, and a soft performance in the Seqirus segment.Company Guidance
Revenue and Profit Growth
CSL Group revenue grew by 5% on a constant currency basis, NPATA increased by 14%, and NPAT grew by 17%. Free cash flow increased by 58%, and the final dividend increased by 12% to USD 1.62 per share.
Successful Product Launches
The new ANDEMBRY product for HAE was approved and launched in the U.S., offering once-monthly dosing with a prefilled auto-injector. Positive uptake noted in Germany and Japan.
Strong Hemophilia Franchise Performance
CSL's hemophilia franchise demonstrated 13% growth at constant currency, with IDELVION achieving 10% growth and ongoing positive uptake of HEMGENIX.
R&D and Pipeline Enhancements
Strategic initiatives aim to enhance CSL's R&D efficiency, targeting over USD 0.5 billion in savings by the end of fiscal year 2028, with plans to reinvest in high-priority opportunities.
Positive Strategic Moves
The company announced a multiyear share buyback program and plans to demerge CSL Seqirus as an independent ASX-listed entity, aiming to create strategic benefits and focus for both entities.
AU:CSL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AU:CSL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 18, 2025 | AU$271.32 | AU$225.50 | -16.89% |
Feb 11, 2025 | AU$254.92 | AU$254.25 | -0.26% |
Aug 12, 2024 | AU$304.29 | AU$290.35 | -4.58% |
Feb 12, 2024 | AU$284.07 | AU$276.25 | -2.75% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does CSL (AU:CSL) report earnings?
CSL (AU:CSL) is schdueled to report earning on Feb 18, 2026, TBA (Confirmed).
What is CSL (AU:CSL) earnings time?
CSL (AU:CSL) earnings time is at Feb 18, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of CSL stock?
The P/E ratio of CSL is N/A.
What is AU:CSL EPS forecast?
AU:CSL EPS forecast for the fiscal quarter 2026 (Q2) is 6.94.